As in AFP and GPC3 detection, ATAD2 may become a prospective molecular biomarker, allowing for the early diagnosis and treatment of HCC patients, thereby avoiding the adverse effects of tumor progression. This evidence concerns the gene GPC3 and hepatocellular carcinoma.